Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma

Systematic review and qualitative meta-analysis

Luigina Micolucci, Most Mauluda Akhtar, Fabiola Olivieri, Maria Rita Rippo, Antonio Domenico Procopio

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Background: Asbestos is a harmful and exceptionally persistent natural material. Malignant mesothelioma (MM), an asbestos-related disease, is an insidious, lethal cancer that is poorly responsive to current treatments. Minimally invasive, specific, and sensitive biomarkers providing early and effective diagnosis in high-risk patients are urgently needed. MicroRNAs (miRNAs, miRs) are endogenous, non-coding, small RNAs with established diagnostic value in cancer and pollution exposure. A systematic review and a qualitative meta-analysis were conducted to identify high-confidence miRNAs that can serve as biomarkers of asbestos exposure and MM. Methods: The major biomedical databases were systematically searched for miRNA expression signatures related to asbestos exposure and MM. The qualitative meta-analysis applied a novel vote-counting method that takes into account multiple parameters. The most significant miRNAs thus identified were then subjected to functional and bioinformatic analysis to assess their biomarker potential. Results: A pool of deregulated circulating and tissue miRNAs with biomarker potential for MM was identified and designated as "mesomiRs" (MM-associated miRNAs). Comparison of data from asbestos-exposed and MM subjects found that the most promising candidates for a multimarker signature were circulating miR- 126-3p, miR-103a-3p, and miR-625-3p in combination with mesothelin. The most consistently described tissue miRNAs, miR-16-5p, miR-126-3p, miR-143-3p, miR- 145-5p, miR-192-5p, miR-193a-3p, miR-200b-3p, miR-203a-3p, and miR-652-3p, were also found to provide a diagnostic signature and should be further investigated as possible therapeutic targets. Conclusion: The qualitative meta-analysis and functional investigation confirmed the early diagnostic value of two miRNA signatures for MM. Large-scale, standardized validation studies are needed to assess their clinical relevance, so as to move from the workbench to the clinic.

Original languageEnglish
Pages (from-to)58606-58637
Number of pages32
JournalOncotarget
Volume7
Issue number36
DOIs
Publication statusPublished - 2016

Fingerprint

Asbestos
MicroRNAs
Meta-Analysis
Biomarkers
Malignant Mesothelioma
Small Untranslated RNA
Validation Studies
Computational Biology
Early Diagnosis
Neoplasms
Databases
Therapeutics

Keywords

  • Asbestos
  • Biomarker
  • Mesothelioma
  • MicroRNA
  • Systematic review

ASJC Scopus subject areas

  • Oncology

Cite this

Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma : Systematic review and qualitative meta-analysis. / Micolucci, Luigina; Akhtar, Most Mauluda; Olivieri, Fabiola; Rippo, Maria Rita; Procopio, Antonio Domenico.

In: Oncotarget, Vol. 7, No. 36, 2016, p. 58606-58637.

Research output: Contribution to journalReview article

@article{3b635e10ec0e4955b59f8dc45416439a,
title = "Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: Systematic review and qualitative meta-analysis",
abstract = "Background: Asbestos is a harmful and exceptionally persistent natural material. Malignant mesothelioma (MM), an asbestos-related disease, is an insidious, lethal cancer that is poorly responsive to current treatments. Minimally invasive, specific, and sensitive biomarkers providing early and effective diagnosis in high-risk patients are urgently needed. MicroRNAs (miRNAs, miRs) are endogenous, non-coding, small RNAs with established diagnostic value in cancer and pollution exposure. A systematic review and a qualitative meta-analysis were conducted to identify high-confidence miRNAs that can serve as biomarkers of asbestos exposure and MM. Methods: The major biomedical databases were systematically searched for miRNA expression signatures related to asbestos exposure and MM. The qualitative meta-analysis applied a novel vote-counting method that takes into account multiple parameters. The most significant miRNAs thus identified were then subjected to functional and bioinformatic analysis to assess their biomarker potential. Results: A pool of deregulated circulating and tissue miRNAs with biomarker potential for MM was identified and designated as {"}mesomiRs{"} (MM-associated miRNAs). Comparison of data from asbestos-exposed and MM subjects found that the most promising candidates for a multimarker signature were circulating miR- 126-3p, miR-103a-3p, and miR-625-3p in combination with mesothelin. The most consistently described tissue miRNAs, miR-16-5p, miR-126-3p, miR-143-3p, miR- 145-5p, miR-192-5p, miR-193a-3p, miR-200b-3p, miR-203a-3p, and miR-652-3p, were also found to provide a diagnostic signature and should be further investigated as possible therapeutic targets. Conclusion: The qualitative meta-analysis and functional investigation confirmed the early diagnostic value of two miRNA signatures for MM. Large-scale, standardized validation studies are needed to assess their clinical relevance, so as to move from the workbench to the clinic.",
keywords = "Asbestos, Biomarker, Mesothelioma, MicroRNA, Systematic review",
author = "Luigina Micolucci and Akhtar, {Most Mauluda} and Fabiola Olivieri and Rippo, {Maria Rita} and Procopio, {Antonio Domenico}",
year = "2016",
doi = "10.18632/oncotarget.9686",
language = "English",
volume = "7",
pages = "58606--58637",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "36",

}

TY - JOUR

T1 - Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma

T2 - Systematic review and qualitative meta-analysis

AU - Micolucci, Luigina

AU - Akhtar, Most Mauluda

AU - Olivieri, Fabiola

AU - Rippo, Maria Rita

AU - Procopio, Antonio Domenico

PY - 2016

Y1 - 2016

N2 - Background: Asbestos is a harmful and exceptionally persistent natural material. Malignant mesothelioma (MM), an asbestos-related disease, is an insidious, lethal cancer that is poorly responsive to current treatments. Minimally invasive, specific, and sensitive biomarkers providing early and effective diagnosis in high-risk patients are urgently needed. MicroRNAs (miRNAs, miRs) are endogenous, non-coding, small RNAs with established diagnostic value in cancer and pollution exposure. A systematic review and a qualitative meta-analysis were conducted to identify high-confidence miRNAs that can serve as biomarkers of asbestos exposure and MM. Methods: The major biomedical databases were systematically searched for miRNA expression signatures related to asbestos exposure and MM. The qualitative meta-analysis applied a novel vote-counting method that takes into account multiple parameters. The most significant miRNAs thus identified were then subjected to functional and bioinformatic analysis to assess their biomarker potential. Results: A pool of deregulated circulating and tissue miRNAs with biomarker potential for MM was identified and designated as "mesomiRs" (MM-associated miRNAs). Comparison of data from asbestos-exposed and MM subjects found that the most promising candidates for a multimarker signature were circulating miR- 126-3p, miR-103a-3p, and miR-625-3p in combination with mesothelin. The most consistently described tissue miRNAs, miR-16-5p, miR-126-3p, miR-143-3p, miR- 145-5p, miR-192-5p, miR-193a-3p, miR-200b-3p, miR-203a-3p, and miR-652-3p, were also found to provide a diagnostic signature and should be further investigated as possible therapeutic targets. Conclusion: The qualitative meta-analysis and functional investigation confirmed the early diagnostic value of two miRNA signatures for MM. Large-scale, standardized validation studies are needed to assess their clinical relevance, so as to move from the workbench to the clinic.

AB - Background: Asbestos is a harmful and exceptionally persistent natural material. Malignant mesothelioma (MM), an asbestos-related disease, is an insidious, lethal cancer that is poorly responsive to current treatments. Minimally invasive, specific, and sensitive biomarkers providing early and effective diagnosis in high-risk patients are urgently needed. MicroRNAs (miRNAs, miRs) are endogenous, non-coding, small RNAs with established diagnostic value in cancer and pollution exposure. A systematic review and a qualitative meta-analysis were conducted to identify high-confidence miRNAs that can serve as biomarkers of asbestos exposure and MM. Methods: The major biomedical databases were systematically searched for miRNA expression signatures related to asbestos exposure and MM. The qualitative meta-analysis applied a novel vote-counting method that takes into account multiple parameters. The most significant miRNAs thus identified were then subjected to functional and bioinformatic analysis to assess their biomarker potential. Results: A pool of deregulated circulating and tissue miRNAs with biomarker potential for MM was identified and designated as "mesomiRs" (MM-associated miRNAs). Comparison of data from asbestos-exposed and MM subjects found that the most promising candidates for a multimarker signature were circulating miR- 126-3p, miR-103a-3p, and miR-625-3p in combination with mesothelin. The most consistently described tissue miRNAs, miR-16-5p, miR-126-3p, miR-143-3p, miR- 145-5p, miR-192-5p, miR-193a-3p, miR-200b-3p, miR-203a-3p, and miR-652-3p, were also found to provide a diagnostic signature and should be further investigated as possible therapeutic targets. Conclusion: The qualitative meta-analysis and functional investigation confirmed the early diagnostic value of two miRNA signatures for MM. Large-scale, standardized validation studies are needed to assess their clinical relevance, so as to move from the workbench to the clinic.

KW - Asbestos

KW - Biomarker

KW - Mesothelioma

KW - MicroRNA

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84988373636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988373636&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9686

DO - 10.18632/oncotarget.9686

M3 - Review article

VL - 7

SP - 58606

EP - 58637

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 36

ER -